THE PHARMA SUMMIT 2013

E-mail Print PDF


Share

THE PHARMA SUMMIT 2013
BACK TO BASICS – THE REAL BUSINESS OF PHARMA
February 28th 2013 • The Dorchester, London

 

Introduction

The press says that it’s all doom and gloom for Big Pharma, which is now teetering on the edge of a “patent cliff” as the last remaining blockbuster drugs reach the end of their patent protection. But people will alwaysneed new medicines. So who exactly is going to be researching and developing them? And how can this process become more profitable? If we were to look into a crystal ball, will the traditional pharma industry still have a valid role to play in R&D in 10 years time, and what will this look like?

Over 18 years, the Pharma Summit has become established as a major industry event for senior pharma executives in strategic roles. And this, the year of the so-called “patent cliff” is when we will be asking crucial questions of the industry’s leaders? Against the background of an increasing trend for diversification in the pharma industry, does it make any sense to try and get back tothe business of developing, making and marketing drugs? Who will be doing R&D? Who will be funding it? How will it be structured? And how can we keep the investor community happy? This is the place to come and find out if pharma as we know it has a future.

Share
These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.
javporn.cc